Key facts
- Simcere Zaiming’s last known valuation is $1.2B (Jun 2025).
- It has raised $148.4M; the latest was IPO in Jan 2026.
- Notable investors include CMG SDIC Fund, Youshan Capital, China Taiping Investment, Apricot Capital (Shanghai), Zhonghe Capital.
- Status: In IPO Registration.
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Simcere Zaiming
- ·The full record, as it builds
Funding rounds
No funding rounds for Simcere Zaiming are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Simcere Zaiming
Developer and manufacturer of innovative oncology drugs designed for treating cancer patients with unmet clinical needs. The company provides drug development services and commercialization capabilities, enabling healthcare providers and patients with access to first-in-class and best-in-class therapeutic solutions.
- Sector
- Healthcare
- HQ
- Haikou, China
- Founded
- 2020
- Employees
- 2,161
- Website
- sparkletx.com/
- Ownership
- In IPO Registration
Simcere Zaiming doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Simcere Zaiming shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Simcere Zaiming in its N-PORT filings yet. We sweep new filings monthly.